MEDICINOVA INC (MNOV) MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
MediciNova, Inc. NASDAQ:MNOV Healthcare · Biotechnology
Mkt Cap $68.91M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
MediciNova to Participate in the Maxim Growth Summit
MediciNova announced management will participate in the Maxim Growth Summit, held October 12-14, 2026 at the Hard Rock Hotel New York.
Management will be available for one-on-one meetings with registered investors; no new clinical or financial data was disclosed.
The release reiterates the clinical-stage pipeline, led by MN-166 (ibudilast) in late-stage trials for ALS and DCM.
• 26d ago AI analysis › Press Release ⚠ 4
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova reported topline results from its Phase 2 MN-001-NATG-202 trial of tipelukast in NAFLD and hypertriglyceridemia associated with type 2 diabetes, a 40-patient, 24-week placebo-controlled study.
MN-001 met statistical significance at Week 4 for triglyceride reduction (31 mg/dL greater than placebo, p=0.015) and at Week 24 for HDL-C (p=0.0048) and HDL-P (p=0.018), but the Week 24 TG difference missed significance (p=0.113), and liver fat and body weight showed only non-significant trends.
The company called the study exploratory proof of concept, said safety was generally favorable with no drug-related serious adverse events, and will evaluate efficacy in a larger trial.
No next-stage design or timeline was disclosed, leaving the tipelukast development path uncertain despite the positive lipid signals.
• 1mo ago AI analysis › Press Release ⚠ 2
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
MediciNova completed the last patient, last visit in the double-blind portion of the Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast) in ALS, with 234 participants randomized across US and Canadian sites.
Topline results from the double-blind portion are expected by the end of 2026, with the full-study LPLV anticipated in March 2027; active participants continue in the open-label extension.
MN-166 holds FDA Fast Track and Orphan Drug designations for ALS, and the primary endpoint is the Combined Assessment of Function and Survival (CAFS). The readout is the company's key near-term catalyst but carries standard binary-outcome risk.
• 1mo ago AI analysis › Press Release ⚠ 2
MediciNova to Participate in Two Investor Conferences in September
MediciNova CEO Yuichi Iwaki and Chief Business Officer David Crean will attend the H.C. Wainwright Global Investment Conference (September 14-16) and the ROTH Capital Healthcare Opportunities Conference (September 29), holding one-on-one investor meetings and joining a 'Frontiers in Neuroscience' panel.
Iwaki reaffirmed the catalyst calendar: topline data from the Phase 2 MN-001-NATG-202 study in metabolic disease is expected by end of Q3, followed by the topline readout from the double-blind phase of the lead program, the Phase 3 COMBAT-ALS study of MN-166 (ibudilast), by year-end.
The company also disclosed a $25.4 million cash position as of Q2 2026, which management says it is carefully managing to ensure sufficient capital -- a thin runway for a clinical-stage biotech carrying Phase 3 programs, keeping financing risk in focus ahead of the readouts.
• 1mo ago AI analysis › Press Release
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova announced it has achieved the target enrollment of 200 patients in the SEANOBI-ALS study, an NIH-funded expanded access program evaluating MN-166 (ibudilast) in ALS patients.
The program is designed to provide access to individuals not eligible for randomized trials, with final patient follow-ups projected to conclude in early 2027 to support data analysis and scientific publications.
MN-166 holds Fast Track and Orphan Drug designations for ALS and remains the company's lead asset, currently in Phase 2b/3 development for the indication.
• 3mo ago AI analysis › Press Release ● Major
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
globenewswire.com • 4mo ago Press Release
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova announced the completion of last patient last visit (LPLV) in its Phase 2 trial MN-001-NATG-202.
The study evaluates MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD associated with type 2 diabetes.
Top-line data from the 24-week, placebo-controlled trial are expected in the third quarter of 2026.
• 5mo ago AI analysis › Press Release
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
globenewswire.com • 6mo ago 
